GSK at ASH 2020
GSK at the American Society of Hematology Annual Meeting 2020
GSK scientists are focused on maximizing survival through the discovery and development of novel oncology medicines that may have life-changing potential. With 14 ongoing research programs, our own R&D is bolstered by the power of collaborations and smart scientific partnerships that will expand the ability of both our portfolio and pipeline to tackle the areas of greatest need in cancer.
At ASH, we are proud to share updates from 13 studies and analyses, including new data from our DRiving Excellence in Approaches to Multiple Myeloma (DREAMM) clinical trial program.
Our presentations at ASH 2020
Click here for more information regarding our participation in the virtual ASH Conference program
Our disease areas of focus
We're committed to developing potential solutions for some of the most challenging diseases with significant unmet medical need.
Follow @GSKUS on Twitter
Running builds perseverance, encourages participation, & patience. It’s great for physical & mental health. @StudentsRunPhl transforms students lives through their program. ✋High-five for their 2020 #GSKimpact Award! 🏃♂️ Meet our winners: gsk.to/3fgfWupq @PhilaFounddeabout 3 days ago
⚽ Kick it up for @StarfinderFound and their 2020 #GSKimpact Award! They inspire success on and off the field by using soccer to inspire social change and transform the lives of youth in underserved communities. Meet our winners: gsk.to/330lYugp @PhilaFounddZabout 3 days ago
GSK US Medical Affairs
This medical information is intended only for healthcare professionals registered to practice in the United States.
A career in oncology
GSK Oncology has a commitment to the discovery and development of new oncology therapies with the life-changing potential of helping patients with cancer, specifically in four areas of cancer research: Cancer Epigenetics, Immuno-Oncology, Oncology Cell and Gene Therapy and Synthetic Lethality.